Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Streetly

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
European Journal of Haematology|January 9, 2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaSally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, et al.
The Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 20, 2021
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myelomaOlwen Westerland, Ashik Amlani, Christian Kelly-Morland, et al.
The British Journal of Radiology|August 14, 2018
National survey of imaging practice for suspected or confirmed plasma cell malignanciesOlwen Amy Westerland, Guy Pratt, Majid Kazmi, et al.
British Journal of Haematology|February 18, 2017
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experienceNicola Maciocia, Andrew Melville, Simon Cheesman, et al.
Oncology and Therapy|February 25, 2021
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, Alessandro Corso, Matthew Streetly, et al.
British Journal of Haematology|July 30, 2015
Time to redefine MyelomaGuy Pratt, Stella Bowcock, Andrew Chantry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 22, 2014
Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioningKavita Raj, Antonio Pagliuca, Kenneth Bradstock, et al.
Journal of Bone Oncology|June 22, 2019
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costsSpyros Kolovos, Guido Nador, Bhuvan Kishore, et al.
Cancer Research Communications|March 6, 2023
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase InhibitorsAna M Metelo, Agnieszka Jozwik, Le Anh Luong, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
European Journal of Haematology|January 9, 2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaSally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, et al.
The Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 20, 2021
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myelomaOlwen Westerland, Ashik Amlani, Christian Kelly-Morland, et al.
The British Journal of Radiology|August 14, 2018
National survey of imaging practice for suspected or confirmed plasma cell malignanciesOlwen Amy Westerland, Guy Pratt, Majid Kazmi, et al.
British Journal of Haematology|February 18, 2017
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experienceNicola Maciocia, Andrew Melville, Simon Cheesman, et al.
Oncology and Therapy|February 25, 2021
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, Alessandro Corso, Matthew Streetly, et al.
British Journal of Haematology|July 30, 2015
Time to redefine MyelomaGuy Pratt, Stella Bowcock, Andrew Chantry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 22, 2014
Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioningKavita Raj, Antonio Pagliuca, Kenneth Bradstock, et al.
Journal of Bone Oncology|June 22, 2019
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costsSpyros Kolovos, Guido Nador, Bhuvan Kishore, et al.
Cancer Research Communications|March 6, 2023
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase InhibitorsAna M Metelo, Agnieszka Jozwik, Le Anh Luong, et al.
Pageof 3